Epsilogen is developing novel IgE antibodies to treat cancer. The company’s lead candidate, MOv18 IgE, is in a Phase I clinical trial in folate receptor alpha positive cancer patients and is the world’s first IgE drug to enter clinical trials. Tim Wilson, CEO talks to Lu Rahman. Epsilogen was founded in April 2017 based around […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
